Regulation of the PMP22 gene through an intronic enhancer

Journal of Neuroscience

Volumn 31, Issue 11, 2011, Pages 4242-4250

  Jones, Erin A ^a   Lopez Anido, Camila ^c   Srinivasan, Rajini ^c   Krueger, Courtney ^c   Chang, Li Wei ^d   Nagarajan, Rakesh ^d   Svaren, John ^b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 2; PERIPHERAL MYELIN PROTEIN 22; TRANSCRIPTION FACTOR SOX10;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE SEQUENCE; GENETIC REGULATION; INTRON; MALE; MOUSE; NERVE CELL DIFFERENTIATION; NONHUMAN; PERIPHERAL NERVE; PMP22 GENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SCHWANN CELL; TISSUE SPECIFICITY; TRANSGENIC MOUSE;

ANIMALS; BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; EARLY GROWTH RESPONSE PROTEIN 2; FEMALE; IMMUNOHISTOCHEMISTRY; INTRONS; MALE; MICE; MICE, TRANSGENIC; MYELIN PROTEINS; MYELIN SHEATH; RATS; RNA, SMALL INTERFERING; SCHWANN CELLS; SOXE TRANSCRIPTION FACTORS;

EID: 79952762905     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5893-10.2011     Document Type: Article

References (68)

1. Adlkofer K, Martini R, Aguzzi A, Zielasek J, Toyka KV, Suter U (1995) Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet 11:274-280.
2. Berger MF, Philippakis AA, Qureshi AM, He FS, Estep PW 3rd, Bulyk ML (2006) Compact, universal DNA microarrays to comprehensively determine transcription-factor binding site specificities. Nat Biotechnol 24:1429-1435. (Pubitemid 44722107)
3. Bondurand N, Girard M, Pingault V, Lemort N, Dubourg O, Goossens M (2001) Human Connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor SOX10. Hum Mol Genet 10:2783-2795. (Pubitemid 34026460)
4. Bosse F, Zoidl G, Wilms S, Gillen CP, Kuhn HG, Müller HW (1994) Differential expression of two mRNA species indicates a dual function of peripheral myelin protein PMP22 in cell growth and myelination. J Neurosci Res 37:529-537. (Pubitemid 24105159)
5. Britsch S, Goerich DE, Riethmacher D, Peirano RI, Rossner M, Nave KA, Birchmeier C, Wegner M (2001) The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev 15:66-78. (Pubitemid 32060683)
6. Chance PF, Alderson MK, Leppig KA, Lensch MW, Matsunami N, Smith B, Swanson PD, Odelberg SJ, Disteche CM, Bird TD (1993) DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell 72:143-151. (Pubitemid 23029701)
7. Choo Y, Castellanos A, García-Hernández B, Sánchez-García I, Klug A (1997) Promoter-specific activation of gene expression directed by bacteriophage-selected zinc fingers. J Mol Biol 273:525-532. (Pubitemid 27488796)
8. Decker L, Desmarquet-Trin-Dinh C, Taillebourg E, Ghislain J, Vallat JM, Charnay P (2006) Peripheral myelin maintenance is a dynamic process requiring constant Krox20 expression. J Neurosci 26:9771-9779. (Pubitemid 44427716)
9. Denarier E, Forghani R, Farhadi HF, Dib S, Dionne N, Friedman HC, Lepage P, Hudson TJ, Drouin R, Peterson A (2005) Functional organization of a Schwann cell enhancer. J Neurosci 25:11210-11217. (Pubitemid 43089566)
10. Felsenfeld G, Groudine M (2003) Controlling the double helix. Nature 421:448-453. (Pubitemid 36157954)
11. Finzsch M, Schreiner S, Kichko T, Reeh P, Tamm ER, Bösl MR, Meijer D, Wegner M (2010) Sox10 is required for Schwann cell identity and progression beyond the immature Schwann cell stage. J Cell Biol 189:701-712.
12. Forghani R, Garofalo L, Foran DR, Farhadi HF, Lepage P, Hudson TJ, Tretjakoff I, Valera P, Peterson A (2001) A distal upstream enhancer from the myelin basic protein gene regulates expression in myelin-forming schwann cells. J Neurosci 21:3780-3787. (Pubitemid 32466470)
13. Fortun J, Dunn WA Jr, Joy S, Li J, Notterpek L (2003) Emerging role for autophagy in the removal of aggresomes in Schwann cells. J Neurosci 23:10672-10680. (Pubitemid 37485281)
14. Fortun J, Go JC, Li J, Amici SA, Dunn WA Jr, Notterpek L (2006) Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression. Neurobiol Dis 22:153-164.
15. Ghislain J, Charnay P (2006) Control of myelination in Schwann cells: a Krox20 cis-regulatory element integrates Oct6, Brn2 and Sox10 activities. EMBO Rep 7:52-58.
16. Giresi PG, Lieb JD (2009) Isolation of active regulatory elements from eukaryotic chromatin using FAIRE (formaldehyde assisted isolation of regulatory elements). Methods 48:233-239.
17. Giresi PG, Kim J, McDaniell RM, Iyer VR, Lieb JD (2007) FAIRE (formaldehyde-assisted isolation of regulatory elements) isolates active regulatory elements from human chromatin. Genome Res 17:877-885. (Pubitemid 46919722)
18. Guennoun R, Benmessahel Y, Delespierre B, Gouézou M, Rajkowski KM, Baulieu EE, Schumacher M (2001) Progesterone stimulates Krox-20 gene expression in Schwann cells. Brain Res Mol Brain Res 90:75-82. (Pubitemid 32497174)
19. Hai M, Bidichandani SI, Patel PI (2001) Identification of a positive regulatory element in the myelin-specific promoter of the PMP22 gene. J Neurosci Res 65:508-519. (Pubitemid 32847144)
20. Hai M, Muja N, DeVries GH, Quarles RH, Patel PI (2002) Comparative analysis of Schwann cell lines as model systems for myelin gene transcription studies. J Neurosci Res 69:497-508. (Pubitemid 34831410)
21. Hogan GJ, Lee CK, Lieb JD (2006) Cell cycle-specified fluctuation of nucleosome occupancy at gene promoters. PLoS Genet 2:e158.
22. Huxley C, Passage E, Manson A, Putzu G, Figarella-Branger D, Pellissier JF, Fontés M (1996) Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet 5:563-569. (Pubitemid 26141268)
23. Huxley C, Passage E, Robertson AM, Youl B, Huston S, Manson A, Sabéran-Djoniedi D, Figarella-Branger D, Pellissier JF, Thomas PK, Fontés M (1998) Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum Mol Genet 7:449-458. (Pubitemid 28120635)
24. Jang SW, Svaren J (2009) Induction of myelin protein zero by early growth response 2 through upstream and intragenic elements. J Biol Chem 284:20111-20120.
25. Jang SW, LeBlanc SE, Roopra A, Wrabetz L, Svaren J (2006) In vivo detection of Egr2 binding to target genes during peripheral nerve myelination. J Neurochem 98:1678-1687.
26. Jang SW, Srinivasan R, Jones EA, Sun G, Keles S, Krueger C, Chang LW, Nagarajan R, Svaren J (2010) Locus-wide identification of Egr2/Krox20 regulatory targets in myelin genes. J Neurochem 115:1409-1420.
27. Jones EA, Jang SW, Mager GM, Chang LW, Srinivasan R, Gokey NG, Ward RM, Nagarajan R, Svaren J (2007) Interactions of Sox10 and Egr2 in myelin gene regulation. Neuron Glia Biology 3:377-387. (Pubitemid 351944157)
28. Kamaraju AK, Bertolotto C, Chebath J, Revel M (2002) Pax3 down-regulation and shut-off of melanogenesis in melanoma B16/F10.9 by interleukin-6 receptor signaling. J Biol Chem 277:15132-15141. (Pubitemid 34952592)
29. Kaya F, Belin S, Bourgeois P, Micaleff J, Blin O, Fontés M (2007) Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul Disord 17:248-253. (Pubitemid 46420772)
30. Kothary R, Clapoff S, Brown A, Campbell R, Peterson A, Rossant J (1988) A transgene containing lacZ inserted into the dystonia locus is expressed in neural tube. Nature 335:435-437.
31. Kuhlbrodt K, Herbarth B, Sock E, Hermans-Borgmeyer I, Wegner M (1998) Sox10, a novel transcriptional modulator in glial cells. J Neurosci 18:237-250. (Pubitemid 28046785)
32. Lau P, Verrier JD, Nielsen JA, Johnson KR, Notterpek L, Hudson LD (2008) Identification of dynamically regulated microRNA and mRNA networks in developing oligodendrocytes. J Neurosci 28:11720-11730.
33. Le N, Nagarajan R, Wang JY, Araki T, Schmidt RE, Milbrandt J (2005a) Analysis of congenital hypomyelinating Egr2Lo/Lo nerves identifies Sox2 as an inhibitor of Schwann cell differentiation and myelination. Proc Natl Acad Sci U S A 102:2596-2601. (Pubitemid 40279422)
34. Le N, Nagarajan R, Wang JY, Svaren J, LaPash C, Araki T, Schmidt RE, Milbrandt J (2005b) Nab proteins are essential for peripheral nervous system myelination. Nat Neurosci 8:932-940.
35. LeBlanc SE, Jang SW, Ward RM, Wrabetz L, Svaren J (2006) Direct Regulation of Myelin Protein Zero Expression by the Egr2 Transactivator. J Biol Chem 281:5453-5460. (Pubitemid 43847640)
36. LeBlanc SE, Ward RM, Svaren J (2007) Neuropathy-associated Egr2 mutants disrupt cooperative activation of myelin protein zero by Egr2 and Sox10. Mol Cell Biol 27:3521-3529. (Pubitemid 46685226)
37. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402-408. (Pubitemid 34164012)
38. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, Saucedo-Cardenas O, Barker DF, Killian JM, Garcia CA, Chakravarti A, Patel PI (1991) DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 66:219-232. (Pubitemid 121001361)
39. Mager GM, Ward RM, Srinivasan R, Jang SW, Wrabetz L, Svaren J (2008) Active gene repression by the EGR2/NAB complex during peripheral nerve myelination. J Biol Chem 283:18187-18197.
40. Magnaghi V, Ballabio M, Roglio I, Melcangi RC (2007) Progesterone derivatives increase expression of Krox-20 and Sox-10 in rat Schwann cells. J Mol Neurosci 31:149-157. (Pubitemid 46742298)
41. Magyar JP, Martini R, Ruelicke T, Aguzzi A, Adlkofer K, Dembic Z, Zielasek J, Toyka KV, Suter U (1996) Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J Neurosci 16:5351-5360. (Pubitemid 26277864)
42. Maier M, Berger P, Suter U (2002) Understanding Schwann cell-neurone interactions: the key to Charcot-Marie-Tooth disease? J Anat 200:357-366.
43. Maier M, Castagner F, Berger P, Suter U (2003) Distinct elements of the peripheral myelin protein 22 (PMP22) promoter regulate expression in Schwann cells and sensory neurons. Mol Cell Neurosci 24:803-817. (Pubitemid 37506021)
44. Mandemakers W, Zwart R, Jaegle M, Walbeehm E, Visser P, Grosveld F, Meijer D (2000) A distal Schwann cell-specific enhancer mediates axonal regulation of the Oct-6 transcription factor during peripheral nerve development and regeneration. EMBO J 19:2992-3003. (Pubitemid 30386770)
45. Nagarajan R, Svaren J, Le N, Araki T, Watson M, Milbrandt J (2001) EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression. Neuron 30:355-368. (Pubitemid 32530581)
46. Notterpek L, Snipes GJ, Shooter EM (1999) Temporal expression pattern of peripheral myelin protein 22 during in vivo and in vitro myelination. Glia 25:358-369. (Pubitemid 29083835)
47. Orfali W, Nicholson RN, Guiot MC, Peterson AC, Snipes GJ (2005) An 8.5-kb segment of the PMP22 promoter responds to loss of axon signals during Wallerian degeneration, but does not respond to specific axonal signals during nerve regeneration. J Neurosci Res 80:37-46. (Pubitemid 40577291)
48. Pareek S, Notterpek L, Snipes GJ, Naef R, Sossin W, Laliberté J, Iacampo S, Suter U, Shooter EM, Murphy RA (1997) Neurons promote the translocation of peripheral myelin protein 22 into myelin. J Neurosci 17:7754-7762. (Pubitemid 27426214)
49. Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontés M (2004) Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 10:396-401. (Pubitemid 38508518)
50. Peirano RI, Wegner M (2000) The glial transcription factor Sox10 binds to DNA both as monomer and dimer with different functional consequences. Nucleic Acids Res 28:3047-3055. (Pubitemid 30624094)
51. Perea J, Robertson A, Tolmachova T, Muddle J, King RH, Ponsford S, Thomas PK, Huxley C (2001) Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A. Hum Mol Genet 10:1007-1018. (Pubitemid 32447778)
52. Reiprich S, Kriesch J, Schreiner S, Wegner M (2010) Activation of Krox20 gene expression by Sox10 in myelinating Schwann cells. J Neurochem 112:744-754.
53. Robertson AM, Perea J, McGuigan A, King RH, Muddle J, Gabreëls-Festen AA, Thomas PK, Huxley C (2002) Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A. J Anat 200:377-390. (Pubitemid 34498532)
54. Rossant J, Zirngibl R, Cado D, Shago M, Giguère V (1991) Expression of a retinoic acid response element-hsplacZ transgene defines specific domains of transcriptional activity during mouse embryogenesis. Genes Dev 5:1333-1344. (Pubitemid 21906042)
55. Sabéran-Djoneidi D, Sanguedolce V, Assouline Z, Lévy N, Passage E, Fontés M (2000) Molecular dissection of the Schwann cell specific promoter of the PMP22 gene. Gene 248:223-231.
56. Schreiner S, Cossais F, Fischer K, Scholz S, Bösl MR, Holtmann B, Sendtner M, Wegner M (2007) Hypomorphic Sox10 alleles reveal novel protein functions and unravel developmental differences in glial lineages. Development 134:3271-3281. (Pubitemid 350018428)
57. Sereda M, Griffiths I, Pühlhofer A, Stewart H, Rossner MJ, Zimmerman F, Magyar JP, Schneider A, Hund E, Meinck HM, Suter U, Nave KA (1996) A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 16:1049-1060. (Pubitemid 26171699)
58. Sereda MW, Meyer zu Hörste G, Suter U, Uzma N, Nave KA (2003) Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 9:1533-1537.
59. Slutsky SG, Kamaraju AK, Levy AM, Chebath J, Revel M (2003) Activation of myelin genes during transdifferentiation from melanoma to glial cell phenotype. J Biol Chem 278:8960-8968. (Pubitemid 36800373)
60. Snipes GJ, Suter U, Welcher AA, Shooter EM (1992) Characterization of a novel peripheral nervous system myelin protein (PMP-22/SR13). J Cell Biol 117:225-238.
61. Suter U, Scherer SS (2003) Disease mechanisms in inherited neuropathies. Nat Rev Neurosci 4:714-726. (Pubitemid 37280151)
62. Suter U, Snipes GJ, Schoener-Scott R, Welcher AA, Pareek S, Lupski JR, Murphy RA, Shooter EM, Patel PI (1994) Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters. J Biol Chem 269:25795-25808. (Pubitemid 24336279)
63. Svaren J, Meijer D (2008) The molecular machinery of myelin gene transcription in Schwann cells. Glia 56:1541-1551.
64. Topilko P, Schneider-Maunoury S, Levi G, Baron-Van Evercooren A, Chennoufi AB, Seitanidou T, Babinet C, Charnay P (1994) Krox-20 controls myelination in the peripheral nervous system. Nature 371:796-799. (Pubitemid 24333867)
65. Verrier JD, Lau P, Hudson L, Murashov AK, Renne R, Notterpek L (2009) Peripheral myelin protein 22 is regulated post-transcriptionally by miRNA-29a. Glia 57:1265-1279.
66. Visel A, Blow MJ, Li Z, Zhang T, Akiyama JA, Holt A, Plajzer-Frick I, Shoukry M, Wright C, Chen F, Afzal V, Ren B, Rubin EM, Pennacchio LA (2009) ChIP-seq accurately predicts tissue-specific activity of enhancers. Nature 457:854-858.
67. Werner MH, Huth JR, Gronenborn AM, Clore GM (1995) Molecular basis of human 46X,Y sex reversal revealed from the three-dimensional solution structure of the human SRY-DNA complex. Cell 81:705-714.
68. Zorick TS, Syroid DE, Arroyo E, Scherer SS, Lemke G (1996) The transcription factors SCIP and Krox-20 mark distinct stages and cell fates in Schwann cell differentiation. Mol Cell Neurosci 8:129-145. (Pubitemid 26386703)